Roivant Sciences (ROIV) Exchange Rate Effect (2023 - 2026)
Roivant Sciences' (ROIV) quarterly Exchange Rate Effect came in at $2.5 million in Q4 2025, up 98.3% YoY from $1.2 million in Q4 2024, and up 103.23% on a QoQ basis from $1.2 million in Q3 2025.
Roivant Sciences (ROIV) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 3 years of Exchange Rate Effect data on file, last reported at $2.5 million in Q4 2025.
- Quarterly Exchange Rate Effect rose 98.3% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.7 million (up 13.93% YoY) and the FY2026 annual result came in at $3.8 million, up 404.28% from the prior year.
- Exchange Rate Effect improved to $2.5 million in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $5.0 million in Q3 2024 to a low of -$2.7 million in Q2 2024.
- A 3-year average of $879000.0 and a median of $1.2 million in 2025 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 446.84% in 2024, down 2241.88% in 2024.
- Tracing ROIV's Exchange Rate Effect over 3 years: stood at $1.5 million in 2023, then decreased by 15.98% to $1.2 million in 2024, then soared by 98.3% to $2.5 million in 2025.
- The last three Exchange Rate Effect figures came in at $2.5 million (Q4 2025), $1.2 million (Q3 2025), and $815000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 315,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 315,000.00 |
| Jun 30, 2026 | 315,000.00 |
| Dec 31, 2025 | 2.45 Mn |
| Dec 31, 2025 | 2.45 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 815,000.00 |
| Jun 30, 2025 | 815,000.00 |
| Dec 31, 2024 | 1.24 Mn |
| Dec 31, 2024 | 1.24 Mn |
| Sep 30, 2024 | 5.04 Mn |
| Sep 30, 2024 | 5.04 Mn |
| Jun 30, 2024 | -2.74 Mn |
| Jun 30, 2024 | -2.74 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Sep 30, 2023 | -1.45 Mn |
| Sep 30, 2023 | -1.45 Mn |
| Jun 30, 2023 | -117,000.00 |
| Jun 30, 2023 | -117,000.00 |